Going up on good volume a good sign. At this juncture, approved as orphan for EPP. Growing market in Middle East, Oceania and Asia. Next quarter should indicate more uptake in USA, not just more Centre’s opening. Highly likely to launch OTC and pediatric EPP soon. Vitiligo trial protocol likely this year. XP early results this year showing DNA repair milestone. Safety profile over 2 decades likely to support move to bigger indications like stroke and neuromuscular indications. What’s good is a one trick orphan pony trading at near $31 - so many fools around me thinks. Somebody might have to eat their swill one day?? GLTA Alternative learned opinions always welcome- tongue and cheek and all!!
Ann: Change of Director's Interest Notice, page-13
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.98 |
Change
0.000(0.00%) |
Mkt cap ! $750.1M | |||
| Open | High | Low | Value | Volume |
| $14.92 | $15.03 | $14.66 | $698.5K | 46.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 124 | $14.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.99 | 106 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |